Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06823859 in CLE or SLE with Cutaneous Manifestations
NCT05879718Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Jul 2023
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of dazukibart in cutaneous lupus erythematosus (CLE), systemic lupus erythematosus (SLE), sponsored by Pfizer. Started Jul 2023; status: terminated.
02
Drugs
dazukibart
03
Conditions
cutaneous lupus erythematosus (CLE)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT05879718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05879718.